Novartis (NVS) announced positive data on breast cancer drug Kisqali (ribociclib) from the late-stage study, NATALEE. This late-breaking data from this four-year post-hoc analysis was presented at the European Society for Medical Oncology ("ESMO") Congress 2024. Data showed that Kisqali, when added to endocrine therapy (ET), reduced the risk of disease recurrence by 28.5% in a broad population of patients with early breast cancer (EBC). Shares of NVS rose 1% on the news. Year to date, shares of Novartis hav ...